MFX key facts
- Operator of cell therapy research and manufacturing platform designed to make bio-processing scalable and affordable for cell and gene therapy.
- It has raised $19.3M; the latest was Accelerator/Incubator in Jan 2024.
- Notable investors include Innovate UK, London & Partners., Future Planet Capital, Cambridge Angels, UK Innovation & Science Seed Fund — 13 tracked in total.
- Status: Privately Held (backing).
Who backs MFX
13+- ·The complete investor list: 13 names
- ·Watch MFX: the Monday email on marks, rounds and moves
MFX funding rounds
No funding rounds for MFX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
MFX investors
13 investors are on record for MFX, including Innovate UK, London & Partners., Future Planet Capital and Cambridge Angels.
About MFX
Operator of cell therapy research and manufacturing platform designed to make bio-processing scalable and affordable for cell and gene therapy. The company's platform specializes in tackling the problems of process control and scalability with cell bioprocessing in particular for autologous cell and gene therapy, enabling biologists to carry out process development by running cell culture conditions in parallel with extreme process control and to scale up cells for manufacturing at a lower cost.
- Sector
- Healthcare
- HQ
- Stevenage, United Kingdom
- Founded
- 2018
- Employees
- 41
- Website
- mfx.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
MFX doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.